Search Results - "LIM, BORA"

Design of PCR assays to specifically detect and identify 37 Lactobacillus species in a single 96 well plate by Kim, Eiseul, Yang, Seung-Min, Lim, Bora, Park, Si Hong, Rackerby, Bryna, Kim, Hae-Yeong

“…Lactobacillus species are used as probiotics and play an important role in fermented food production. However, use of 16S rRNA gene sequences as standard…”
Get full text

Platinum Monolayer Electrocatalyst on Gold Nanostructures on Silicon for Photoelectrochemical Hydrogen Evolution by Kye, Joohong, Shin, Muncheol, Lim, Bora, Jang, Jae-Won, Oh, Ilwhan, Hwang, Seongpil

“…Pt monolayer decorated gold nanostructured film on planar p-type silicon is utilized for photoelectrochemical H2 generation in this work. First, gold…”
Get full text

Inflammatory breast cancer: a proposed conceptual shift in the UICC–AJCC TNM staging system by Fouad, Tamer M, MD, Barrera, Angelica M Gutierrez, MS, Reuben, James M, PhD, Lucci, Anthony, MD, Woodward, Wendy A, MD, Stauder, Michael C, MD, Lim, Bora, MD, DeSnyder, Sarah M, MD, Arun, Banu, MD, Gildy, Babiera, MD, Valero, Vicente, MD, Hortobagyi, Gabriel N, MD, Ueno, Naoto T, Dr

“…Summary In the absence of histological criteria that distinguish between inflammatory and non-inflammatory breast cancer, diagnosis of inflammatory breast…”
Get full text

Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites by El-Deiry, Wafik S., Vijayvergia, Namrata, Xiu, Joanne, Scicchitano, Angelique, Lim, Bora, Yee, Nelson S., Harvey, Harold A., Gatalica, Zoran, Reddy, Sandeep

“…Metastatic colorectal cancer (mCRC) carries a poor prognosis with an overall 5-year survival of 13.1%. Therapies guided by tumor profiling have suggested…”
Get full text

Update on systemic treatment for newly diagnosed inflammatory breast cancer by Chainitikun, Sudpreeda, Saleem, Sadia, Lim, Bora, Valero, Vicente, Ueno, Naoto T.

“…[Display omitted] Inflammatory breast cancer (IBC) is a rare and aggressive disease, accounting for 2–4% of new cases of breast cancer. Owing to its aggressive…”
Get full text

Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer by Torres-Adorno, Angie M, Lee, Jangsoon, Kogawa, Takahiro, Ordentlich, Peter, Tripathy, Debu, Lim, Bora, Ueno, Naoto T

“…Inflammatory breast cancer (IBC), diagnosed clinically, and triple-negative breast cancer (TNBC), diagnosed by molecular receptor status, are the two most…”
Get full text

Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy by Soundararajan, Rama, Fradette, Jared J, Konen, Jessica M, Moulder, Stacy, Zhang, Xiang, Gibbons, Don L, Varadarajan, Navin, Wistuba, Ignacio I, Tripathy, Debasish, Bernatchez, Chantale, Byers, Lauren A, Chang, Jeffrey T, Contreras, Alejandro, Lim, Bora, Parra, Edwin Roger, Roarty, Emily B, Wang, Jing, Yang, Fei, Barton, Michelle, Rosen, Jeffrey M, Mani, Sendurai A

“…Over the last decade, both early diagnosis and targeted therapy have improved the survival rates of many cancer patients. Most recently, immunotherapy has…”
Get full text

Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy by Crespo, James, Sun, Hongxia, Wu, Jimin, Ding, Qing-Qing, Tang, Guilin, Robinson, Melissa K, Chen, Hui, Sahin, Aysegul A, Lim, Bora

“…The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guideline on HER2 testing in breast cancer permits reclassification…”
Get full text

Pathological complete response of adding targeted therapy to neoadjuvant chemotherapy for inflammatory breast cancer: A systematic review by Chainitikun, Sudpreeda, Espinosa Fernandez, Jose Rodrigo, Long, James P, Iwase, Toshiaki, Kida, Kumiko, Wang, Xiaoping, Saleem, Sadia, Lim, Bora, Valero, Vicente, Ueno, Naoto T

“…The current use of targeted therapy plus neoadjuvant chemotherapy for inflammatory breast cancer (IBC) is based on data extrapolated from studies in non-IBC…”
Get full text

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype by Harano, Kenichi, Wang, Ying, Lim, Bora, Seitz, Robert S, Morris, Stephan W, Bailey, Daniel B, Hout, David R, Skelton, Rachel L, Ring, Brian Z, Masuda, Hiroko, Rao, Arvind U K, Laere, Steven Van, Bertucci, Francois, Woodward, Wendy A, Reuben, James M, Krishnamurthy, Savitri, Ueno, Naoto T

“…In patients with triple-negative breast cancer (TNBC), tumor-infiltrating lymphocytes (TILs) are associated with improved survival. Lehmann et al. identified 4…”
Get full text

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer by Kai, Megumi, Marx, Angela N., Liu, Diane D., Shen, Yu, Gao, Hui, Reuben, James M., Whitman, Gary, Krishnamurthy, Savitri, Ross, Merrick I., Litton, Jennifer K., Lim, Bora, Ibrahim, Nuhad, Kogawa, Takahiro, Ueno, Naoto T.

“…Talimogene laherparepvec (T-VEC) is an immunotherapy that generates local tumor lysis and systemic antitumor immune response. We studied the efficacy of…”
Get full text

Prognostic/predictive markers in systemic therapy resistance and metastasis in breast cancer by Hobbs, Evthokia A., Chen, Natalie, Kuriakose, Alphi, Bonefas, Elizabeth, Lim, Bora

“…Breast cancer is a highly heterogeneous group of diseases posing a significant challenge in biomarker-driven research and the development of effective targeted…”
Get full text

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference by Ueno, Naoto T, Espinosa Fernandez, Jose Rodrigo, Cristofanilli, Massimo, Overmoyer, Beth, Rea, Dan, Berdichevski, Fedor, El-Shinawi, Mohamad, Bellon, Jennifer, Le-Petross, Huong T, Lucci, Anthony, Babiera, Gildy, DeSnyder, Sarah M, Teshome, Mediget, Chang, Edward, Lim, Bora, Krishnamurthy, Savitri, Stauder, Michael C, Parmar, Simrit, Mohamed, Mona M, Alexander, Angela, Valero, Vicente, Woodward, Wendy A

“…National and international experts in inflammatory breast cancer (IBC) from high-volume centers treating IBC recently convened at the 10th Anniversary…”
Get full text

Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research by Espinosa Fernandez, Jose Rodrigo, Eckhardt, Bedrich L, Lee, Jangsoon, Lim, Bora, Pearson, Troy, Seitz, Rob S, Hout, David R, Schweitzer, Brock L, Nielsen, Tyler J, Lawrence, O Rayne, Wang, Ying, Rao, Arvind, Ueno, Naoto T

“…The original algorithm that classified triple-negative breast cancer (TNBC) into six subtypes has recently been revised. The revised algorithm (TNBCtype-IM)…”
Get full text

Identification of frequent somatic mutations in inflammatory breast cancer by Matsuda, Naoko, Lim, Bora, Wang, Ying, Krishnamurthy, Savitri, Woodward, Wendy, Alvarez, Ricardo H., Lucci, Anthony, Valero, Vicente, Reuben, James M., Meric-Bernstam, Funda, Ueno, Naoto T.

“…Purpose Inflammatory breast cancer is an aggressive form of breast cancer that shows distinct clinical features from non-inflammatory breast cancer. Genomic…”
Get full text

Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications by He, Jing, Huo, Lei, Ma, Junsheng, Zhao, Jun, Bassett, Roland L, Sun, Xiaoping, Ueno, Naoto T, Lim, Bora, Gong, Yun

“…Abstract Objectives Inflammatory breast carcinoma (IBC) is rare but is the most lethal type of breast cancer. Programmed death ligand 1 (PD-L1) expression in…”
Get full text

Role of MR Imaging in Neoadjuvant Therapy Monitoring by Le-Petross, Huong T., MD, Lim, Bora, MD

“…Neoadjuvant chemotherapy (NAC) has become an important treatment approach for stage II/III breast cancers to downsize tumor and enable breast-conserving…”
Get full text

Genetic and Pharmacological Screens Converge in Identifying FLIP, BCL2, and IAP Proteins as Key Regulators of Sensitivity to the TRAIL-Inducing Anticancer Agent ONC201/TIC10 by Allen, Joshua E, Prabhu, Varun V, Talekar, Mala, van den Heuvel, A Pieter J, Lim, Bora, Dicker, David T, Fritz, Jennifer L, Beck, Adam, El-Deiry, Wafik S

“…ONC201/TIC10 is a small-molecule inducer of the TRAIL gene under current investigation as a novel anticancer agent. In this study, we identify critical…”
Get full text

Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer by Lee, Hee Jin, Park, In Ah, Park, So Yeon, Seo, An Na, Lim, Bora, Chai, Yun, Song, In Hye, Kim, Na Eun, Kim, Joo Young, Yu, Jong Han, Ahn, Jin-Hee, Gong, Gyungyub

“…The clinical behavior of human epidermal growth factor 2 (HER2)-positive breast cancer, including pathologic complete response rate and pattern of relapse and…”
Get full text

MEK and PI3K catalytic activity as predictor of the response to molecularly targeted agents in triple-negative breast cancer by Sato, Natsuki, Wakabayashi, Masayuki, Nakatsuji, Masatoshi, Kashiwagura, Haruka, Shimoji, Naohiro, Sakamoto, Shiho, Ishida, Atsuko, Lee, Jangsoon, Lim, Bora, Ueno, Naoto T., Ishihara, Hideki, Inui, Takashi

“…Hyper-activation of the MAPK and PI3K-AKT pathways is linked to tumour progression in triple-negative breast cancer (TNBC). However, clinically effective…”
Get full text